搜索筛选:
搜索耗时3.4581秒,为你在为你在102,285,761篇论文里面共找到 4 篇相符的论文内容
发布年度:
[期刊论文] 作者：Amy L.Cummings,Edward B.Garon,
来源：癌症生物学与医学（英文版） 年份：2017
The recent approval of pembrolizumab as second-line treatment for any solid tumor with high-level microsatellite instability or mismatch repair deficiency agnos...
[会议论文] 作者：Naiyer A.Rizvi,Edward B.Garon,Amita Patnaik,Leena Gandhi,Natasha B.Leighl,Ani Sarkis Balmanoukian,Jonathan,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design...
Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts)
[会议论文] 作者：Edward B.Garon,Natasha B.Leighl,Naiyer A.Rizvi,George R.Blumenschein Jr.,Ani Sarkis Balmanoukian,Joseph,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells...
[期刊论文] 作者：显示全部作者", class=",showAll",>,,Dong-Wan KIM,Silvia NOVELLO,Miyako SATOUCHI,Yi-Long WU,Edward B.GARON,
来源：中国肺癌杂志 年份：2022
背景与目的 我们回顾性评估了程序性死亡配体1（programmed death ligand 1, PD-L1）阳性非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的预后，以比较基线（即入组时）脑转移与帕博利珠单抗及化疗的疗效关系。方法 我们汇总分析了KEYNOTE-001（NCT01295827）、KEYNOTE-......
相关搜索：
